To examine a possible protective effect of exog enous glial cell line-derived neurotrophic factor (GDNF) gene expression against ischemic brain injury, a replication defective adenoviral vector containing GDNF gene (Ad GDNF) was directly injected into the cerebral cortex at I day before 90 minutes of transient middle cerebral artery occlusion (MCAO) i\l rats. 2,3,5-Triphenyltetrazolium chloride staining showed that infarct volume of the Ad-GDNF-injected group at 24 hours after the transient MCAO was significantly smaller than that of vehicle-or Ad-LacZ-treated group. Enzyme-linked immunosorbent assay (ELISA) for immunoreactive GDNF demonstrated that GDNF gene products in the Ad-GDNF injected group were higher than those of vehicle-treated group at 24 hours after transient MCAO. Immunoreactive GDNF Glial cell line-derived neurotrophic factor (GDNF) has a potent neuroprotective effect on a variety of neuronal damage in vitro or in vivo (Lin et aI., 1993; Henderson et aI., 1994; Beck et aI., 1995; Li et aI., 1995; Tomac et aI., 1995). Our previous papers and another report have also demonstrated the amelioration of ischemic brain injury by GDNF application after middle cerebral artery occlu-
sion (MCAO) model in rodents (Abe et aI., 1997a; Wang et aI., 1997; Kitagawa et aI., 1998a) . Therefore, GDNF could be one of the most potent candidates for acute cerebrovascular injury as well as neurodegenerative dis orders such as Parkinson's disease (Lin et aI., 1993; Tomac et aI., 1995) . However, in regard to clinical ap plication of this protein, administration could remain dif ficult. GDNF cannot be effectively delivered to the brain parenchymal lesion after the vascular injection because of the blood brain barrier. Furthermore, intracerebroven tricular or intraparenchymal injection could not be fre quently applicable in the clinical situation.
Gene delivery systems using virus vectors have been reported in many fields including not only genetic dis eases but also in some acquired diseases such as cancer or cardiovascular disease (Nabel, 1995; Verma and So mia, 1997) . Some genes have also been successfully transferred into the brain and have shown protective ef fects against ischemic brain injury (Betz et aI., 1995; Linnik et aI., 1995; Lawrence et a\., 1997; Yang G-Y et aI., 1997; Yang et aI., 1998; Yenari et aI., 1998) . Adeno virus-mediated gene expression of an interleukin-I re ceptor antagonist reduced brain ischemic injury after MeAO in rodents (Betz et aI., 1995; Yang G-Y et aI., 1997; Yang et aI., 1998) . Herpes simplex virus -mediated HSP72 gene was neuroprotective in a rat model of stroke and epilepsy (Yenari et aI., 1998) . Therefore, gene therapy for cerebrovascular disease could become one potentially better therapy in the near future (Heistad and Faraci, 1996) .
Recently, our group demonstrated successful adenovi rus-mediated LacZ gene transfer into normal or ischemic rodent brain (Abe et aI., 1997b,c; Kitagawa et aI., 1998b,c) . Replication-defective adenovirus-mediated gene transfer has some advantages for gene therapy for stroke in comparison with those mediated by the other vectors such as retrovirus, herpes simplex virus, etc. Ad enovirus vectors could efficiently infect the terminated cells as well as proliferative ones. Adenovirus vectors are less toxic than the others, although inflammatory reac tions (Byrnes et aI., 1995; Newman et aI., 1995) or tran sient cytotoxicity has been reported (Kitagawa et aI., 1998b,c) . Moreover, the transient nature of gene expres sion, considered a disadvantage for other types of disor ders, could turn out to be positive for acute brain diseases (Abe et aI., 1997b) .
The mechanism of the neuroprotective effect of GDNF is not clearly understood. Some apoptotic signals may be important in the development of ischemic neu ronal cell death. Recently, it has been reported that caspases-3 and cytochrome c may play a pivotal role in apoptotic cell death after mitochondrial apoptotic signal pathways regulated by bcl-2 family genes (Kluck et aI., 1997; Yang J et aI., 1997) . Our previous reports showed an induction of caspases after ischemic injury in the rat brain and an attenuation of ischemic brain injury by GDNF associated with the suppression of caspases in duction (Kitagawa et aI., 1998a) . Thus, we prepared an adenovirus vector containing the GDNF gene (Ad GDNF), and a possible protective effect of the Ad GDNF transfer into rat brain was examined after tran sient MeAO in association with modifications of apop totic signals.
MATERIALS AND METHODS

Adenoviral vector
The recombinant adenoviral vector used in this study was based on type 5 adenovirus that was essentially the same as in previous reports (Bajocchi et aI., 1993; Setoguchi et aI., 1994; Abe et al 1997b) . In brief, the E3 region of the adenovirus genome was deleted, and a cassette containing cDNA for rat GDNF or Escherichia coli lacZ gene (used as a control vector) driven by cytomegalovirus promoter and SV40 polyadenyla tion signal was inserted into the E I region of the adenovirus genome by homologous recombination. With this promoter, the rat GDNF or E. coli lacZ gene of the episomally located ad-enovirus vector may be transcribed as mRNA in the nucleus, and the mRNA translated into the protein in the cytoplasm. The adenoviral vector, designated as Ad-GDNF or Ad-LacZ, was propagated in 293 cells (CRL1573; American Type Collection) and purified and titered as previously described (Bajocchi et aI., 1993; Setoguchi et aI., 1994; Abe et aI., 1997b) .
Western blotting for glial cell line-derived neurotrophic factor gene expression
The 293 cells were cultured with Eagle's Essential Medium containing 10% heat-inactivated fetal bovine serum, 2 mmollL glutamine, 50 U/mL penicillin, and 50 fLg/mL streptomycin with or without Ad-GDNF (lO R plaque-forming units [pful/ mL) at 37°C for 48 hours. After incubation, media were col lected, centrifuged at 2,000g, and the supernatants were used for Western blotting. Culture supernatants (12.5 fLL) or stan dard GDNF (25 ng) (recombinant human GDNF; Promega, Madison, WI, U.S.A.) were dissolved in Laemmli's sample buffer (Laemmli, 1970) , separated on 8 to 16% sodium dodecyl sulfate (polyacrylamide gel electrophoresis) and electrophoret ically transferred to polyvinylidene difluoride membranes for 2 hours. Briefly, the polyvinyJidene difluoride membranes were incubated for 1 hour at room temperature with 150 mmollL NaCI, 50 mmol/L Tris/HCI, pH 7.5, (Tris buffered saline; TBS) containing 0.04% NP-40 and 3% bovine serum albumin (frac tion V), followed by overnight incubation at 4°C with anti GDNF polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, U.S.A.). The primary antibody was diluted in TBS containing 1 % bovine serum albumin (1: 100). The poly vinylidene difluoride membranes were washed three times for 15 minutes each at room temperature in TBS and then incu bated for 60 minutes with alkaline phosphatase-conjugated goat antirabbit IgG (H+L). The blots were stained with 5-bromo-4chloro-3-indoyl phosphate-p-toluidine salt and p-nitroblue tet razolium chloride as described in the BIO-RAD instruction manual.
In vivo adenovirus-mediated glial cell line-derived neurotrophic factor gene transfer Male adult Wistar rats (body weight: 250 to 280 g) were used in this experiment. Adenovirus vector injection was performed according to our previous report with a slight modification (Abe et aI., 1997b) . Briefly, the animals were anesthetized with an intraperitoneal injection of pentobarbital (10 mg/250 g rat) and were immobilized using a stereotactic frame (SR-5N, Na rishige, Tokyo, Japan). A burr hole with a diameter of 2 mm was carefully made in the skull by an electric dental drill to avoid traumatic brain injury. The location of the burr hole was 3 mm posterior and 5 mm lateral to the right of bregma, which is located at the upper part of the MCA. Dura mater was pre served at this time. The animals were allowed to recover at ambient atmosphere.
On the next day, at about 24 hours after the drilling, the rats were anesthetized by inhalation of a nitrous oxide-oxygen halothane (68%-30%-2%) mixture, and their heads were fixed in the stereotactic frame. Ad-GDNF, Ad-LacZ (l0 8 pfu in 10 fLL of vector vehicle consisting of 10 mmollL Tris-HCI, pH 7.4, 1 mmollL MgCI2, and 10% glycerol), or vehicle solution was administered to the ipsilateral cortex via the burr hole through the dura mater at a depth of 4 mm from the surface of the skull bone at an angle of 24° laterally using a 10-fLL sterile Hamilton syringe (the Gastight Highperformance Syringe, Hamilton, Reno, NE, U.S.A.) and a 26-gauge needle (0.47 mm outer diameter). The injections (10 fLL) were slowly completed in 10 minutes. During the injection, the needle was gradually withdrawn at a rate of 0.4 mmlmin.
Transient middle cerebral artery occlusion
At approximately 24 hours after the virus vector injection, the rats were again anesthetized by inhalation of a nitrous ox ide-oxygen-halothane (69%-30%-1 %) mixture during the sur gical procedure. The right MCA was occluded by the insertion of a nylon thread through the common carotid artery as de scribed in our previous reports (Hayashi et aI., 1998a; Kitagawa et aI., 1998a) . Body temperature was maintained at 37 ± 0.3°C during the surgical preparation for MCA occlusion using a heat pad (BWT-lOO, Bio Research Center Co., Ltd, Nagoya, Japan) and heating lamp. The blood flow was restored by removal of the nylon thread after 90 minutes of transient ischemia. Blood samples (90 fLL) were collected before MCAO (-1.5 h) or at 0, 8, or 24 hours after 90 minutes of reperfusion from ventral tail artery for measurement of Pao2, Paco2, and pH (pH/Blood Gas Analyzer, CIBA CORNING 238, CHIRON, Tokyo Japan). Body temperature was also monitored before MCAO or at 0, 8, or 24 hours after reperfusion with a rectal probe (RET-2, Physitemp Instruments Inc., Clifton, AZ, U.S.A.). The animals were allowed to recover at ambient tem perature (21 to 24°C) until the time of sampling. The experi mental protocol and procedures were approved by the Animal Committee of the Okayama University Medical School.
Estimation of brain injury after transient middle cerebral artery occlusion
To examine an effect of Ad-GDNF on infarct size after tran sient MCAO, the rat forebrains were removed and divided into 6 coronal (2 mm each) sections at 24 hours of reperfusion with vehicle (n F 9), Ad-LacZ (n = 6), or Ad-GDNF (n = 9) treatment. The coronal sections (designated S-\ to S-6 from frontal pole to midbrain) were stained with saline containing 2% 2,3,5-triphenyltetrazolium chloride at 37°C for 30 minutes, after which sections were fixed in 10% neutralized formalin, according to a technique reported previously (Bederson et aI., 1986) . The five infarct areas between each adjoining slice were measured by Scion Image software, version 1.62a, and then the infarct areas on each slice were summed and mUltiplied by slice thickness to give the infarct volume. In this experiment, re gional cerebral blood flow (rCBF) of right frontoparietal cortex region was measured before or immediately after occlusion (-1.5 hours) or reperfusion (0 hours) respectively, and at 8 or 24 hours after the reperfusion through the burr hole using a laser blood flowmeter (FJo-C I, Omegawave, Tokyo, Japan).
Enzyme-linked immunosorbent assay for glial cell line-derived neurotrophic factor
For measurement of GDNF protein content, the S-4 coronal section, which contained the needle injection site, was homog enized with buffer (0.01 mollL Tris-HCI buffer, pH 7.5, con taining 0.1 mollL NaCl, I mmollL ethylenediaminetetraacetic acid (EDTA), and I mmollL phenylmethylsulfonyl fluoride) using a Polytron. The homogenate was centrifuged at 1O,000g for 20 minutes at 4°C, and then the supernatant was collected as a sample for GDNF enzyme-linked immunosorbent assay (ELISA) assay. A specific GDNF sandwich immunoassay with a chicken polyclonal antibody for human GDNF was per formed in the 96-well immunoassay plate (Nunc MaxiSorp Nalge Nunc Int., Rochester, NY, U.S.A.), which was precoated with the anti-GDNF monoclonal antibody, using the kit (GDNF Emax Immunoassay Systems, Promega). After overnight incu bation at 4°C, reaction of a second antibody-HRP conjugate (kit component) for chicken IgY was performed, followed by color development with TMB solution (kit component). After Vol. 19, No. 12, 1999 the stop reaction with I mollL phosphoric acid, OD4 S 0 was measured by a 96 well plate reader, and GDNF protein content of each sample was calculated. Using this system, immunore active GDNF in the samples can be quantitated in the range of 16 to 1,000 pg/mL.
Histologic study
For the histologic staining of DNA fragmentation, GDNF, caspase-3, and cytochrome c, the rat forebrains were removed and quickly frozen in a powdered dry ice at I day after vehicle (n = 3) or Ad-GDNF (n = 3) injection, or at 24 hours after transient MCAO (2 days after injection) of both vehicle-(n = 3) and Ad-GDNF-(n = 3) treated groups. Sham control samples (n = 2) were also collected in the same way without the drug injection and MCAO. Coronal sections at the caudate and dorsal hippocampal levels were cut on a cryostat at -18°C to a 10-fLm thickness and collected on glass slides.
For detection of DNA fragmentation, terminal deoxynucleo tidyl dUTP nick-end labeling (TUNEL) was performed with a kit (T ACS TdT in Situ Apoptosis Detection Kit #80-4625-00, Genzyme, Cambridge, MA, U.S.A.). In brief, after the "fixation with 10% neutralized formalin," a set of brain sections was washed 3 times with cold phosphate-buffered saline (PBS, pH 7.4) and made permeable with CytoPore (kit component) for 20 minutes. After blocking endogenous peroxidase with 2% H202 for 5 minutes, double-strand breaks in genomic DNA were detected with the mixture of terminal deoxynucleotidyl trans ferase (TdT) dNTP Mix, TdT enzyme, and TdT Mn 2 + (kit components) in Ix TdT labeling buffer for I hour at 37°C. The reaction was stopped with 1 x STOP buffer, followed by incu bation for 20 minutes with streptavidin-horseradish peroxidase, and the staining was developed with 2,3' -diaminobenzidine tetrahydrochloride (0,5 mg/mL in 50 mmolll Tris-HCI buffer, pH 7.4).
Immunostaining for GDNF, caspase-3, and cytochrome c was performed by avidin-biotin-peroxidase method using a kit (PK-61 0 I for GDNF or cytochrome c, or PK-6105 for caspase-3, Vector Laboratories, Burlingame, CA, U.S.A.). The fresh frozen sections were fixed for 10 minutes in ice-cold acetone and air-dried. Then the sections were rinsed 3 times in PBS (pH 7.4). After blocking with 10% normal serum (kit components) for 2 hours, the slides were incubated for 16 hours at 4°C with a first antibody: a rabbit polyclonal antibody against GDNF (D-20), cytochrome c (H-104), and a goat polyclonal antibody against caspase-3 (CPP32 p20, L-18) (Santa Cruz Biotechnol ogy Inc., catalogue #sc-328, sc-7159, or sc-1225, respectively), diluted in PBS (1/200) containing 10% normal serum and 0.3% Triton X-lOO. Some sections were treated simultaneously with out the first antibody. The specificity of these antibodies was also confirmed by Western blot analysis using those antibodies that showed a 20-kDa, 12-kDa, or 20-kDa single band of GDNF (Fig. I, lane 3) , cytochrome c (data not shown), or caspase-3 p20 subunit (Hayashi et aI., 1998b) , respectively. Endogenous peroxidase was blocked for 20 minutes with PBS containing 0.3% H202 and 10% methanol. The sections were then washed and incubated for 2 hours with the biotinylated second antibody (I :200), in the buffer, followed by incubation, for 30 minutes with avidin-biotin-horseradish peroxidase com plex. Staining was developed with 2,3'-diaminobenzidine tet rahydrochloride (0.5 mg/mL, in 50 mmol/L Tris-HCL buffer, pH 7.4), and lightly counterstained with Mayer hematoxylin.
The sections were examined by light microscope, and the stained cells in 0.25 mm 2 of three random MCA areas were counted, summed, and categorized into 4 grades as follows: no tively. In addition, the number of TUNEL, caspase-3, or cyto chrome c positive cells in the cerebral cortex of the Ad-GDNF treated samples (n = 6) was statistically compared with that of the vehicle group.
Statistical analyses
Statistical analysis was performed using Student's t-test for GDNF ELISA assay, one-way analysis of variance (ANOV A) for infarct volume, two-way analysis of variance followed by Bonferroni post hoc test for infarct area, analysis of variance repeated measure for physiologic and reBF data, and Mann Whitney test for the number of TUNEL, caspase-3, or cyto chrome c positive cells, respectively.
RESULTS
Adenoviral glial cell line-derived neurotrophic factor gene expression in vitro
Rat GDNF protein content in the supernatant from the culture medium of 293 cells, which was infected by Ad GDNF, was 71.5 ng/mL measured by GDNF ELISA assay using a kit, whereas GDNF protein was not de tected in the control medium (data not shown). Western blotting demonstrated that the supernatant showed a clear 20-kDa band of rat GDNF (Fig. I, lane 3) , while standard recombinant human GDNF (rhGDNF) showed a 16-kDa single band (Fig. I, lane 2) .
Effect of adenoviral vector containing glial cell line-derived neurotrophic factor on infarction after middle cerebral artery occlusion There were no significant differences in blood gases, pH, and rectal temperature among vehicle-, Ad-LacZ-, and Ad-GDNF-treated groups before MCAO, or at 0, 8, or 24 hours after the reperfusion (Table 1) . Rectal tem perature in both groups increased at 0 hour of the reper fusion and then declined to the basal level by 8 hours after the reperfusion.
Regional CBF of both the vehicle-, Ad-LacZ-, and Ad-GDNF-treated groups was reduced to approximately 40% of the control immediately after MCAO and recov ered to the baseline after reperfusion by withdrawing the nylon thread (Fig. 2) . Although a slight increase of rCBF in the case of the Ad-GDNF-treated group compared to that of the vehic1e-or the Ad-LacZ-treated group was observed, there was no significant difference between these three groups (Fig. 2) . Although infarction in the brain sections of the sham control group could not be observed, infarct volumes of the vehicle-, Ad-LacZ-, and Ad-GDNF-treated groups at 24 hours after 90 minutes of transient MCAO were 209.2 ± 35.8 mm 3 (mean ± SD, n = 9), 213.3 ± 59. 1 mm 3 (n = 6), and 97.6 ± 71.5 mm 3 Data represents mean ± SD. RT, rectal temperature. There were no significant differences in each value between the vehicle, Ad-LacZ, and Ad-GDNF groups by ANOY A repeated measure analysis.
H. K1TAGAWA ET AL. Temporal profile of regional CBF after 90 minutes of transient MCAO_ Regional CBF reduced to about 40% of basal line immediately after MCAO occlusion (-1.5 hours) and restored to baseline after reperfusion (0 hours) in both vehicle-(n = 9, -A-), Ad-LacZ-(n = 6, -0-), and Ad-GDNF-treated (n = 9, -e-) groups. There was no significant difference in CBF between these three groups. Data are expressed as mean ± SD.
(n = 9; P < 0.00 1 versus the vehicle-and Ad-LacZ treated groups), respectively (Fig. 3A) . Infarct areas of two or three coronal sections (4, 6, and 8 mm caudal from frontal pole) from the Ad-GDNF-treated group were also significantly smaller than those of the vehicle or the Ad-LacZ groups (Fig. 3B) , respectively.
Detection of immunoreactive glial cell line-derived neurotrophic factor
ELISA assay for GDNF revealed that rat GDNF con tents at 24 hours after MeAO in an S-4 slice of the Ad-GDNF-treated group (222.6 ± 49.5 pg/lOO mg tissue, n = 9) were about 10 times higher (P < 0.0 1) than those of the vehicle-treated group (22.9 ± 34.6, n = 9) ( Fig. 4) . Immunoreactive GDNF was not detected in any region including around the needle track (Fig. 5a , arrows) be fore MeAO (24 hours after vehicle injection) in the ve hicle-treated group, whereas GDNF-positive cells were detected in the cortex (Fig. 5b, arrowheads) near the needle track (Fig. 5b, arrows) before MeAO in the Ad GDNF-treated group. At 24 hours after the reperfusion, GDNF-positive cells (Fig. 5d, arrowheads) were also de tected in the cortex near the needle track in the Ad GDNF-treated group, but not or only slightly in the ve hicle group (Fig. 5c ). There were no staining cells in the sample treated without primary antibody as a negative control (data not shown).
Effect of adenoviral vector containing glial cell
line-derived neurotrophic factor on the changes of TUNEL, caspase-3, or cytochrome c stainings There were no TUNEL or caspase-3-positive cells in the sham control brain (Figs. 6a and 6d) , whereas cyto chrome c-stained cells were slightly detected in layers IV to V of the ipsilateral (Fig. 6g, arrowheads) lateral frontoparietal somatosensory cortex. TUNEL positive cells were markedly increased in ipsilateral cor tex (Fig. 6b , Table 2 ) and caudate ( the Ad-GDNF-treated group, the number of TUNEL positive cells was obviously smaller, especially in the cortex (Fig. 6c, arrowhead) , than that in the vehicle group (Table 2) . Caspase-3-or cytochrome c-positive
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Cyto C neurons were also markedly increased in the vehicle group at 24 hours after transient MCAO in both ipsilat eral cortex ( Figs. 6e and 6h , arrowheads) and caudate, whereas those positive cells were reduced in the Ad GDNF-treated group (Figs. 6f and 6i , arrowheads, Table  2 ). Nonparametric statistical analysis (Mann-Whitney test) also showed that the number of positive cells in the cortex of the Ad-GDNF-treated group was significantly smaller than that in the vehicle group (TUNEL, or caspase-3, P < 0.0 1; cytochrome c, P < 0.05). In the ipsilateral hippocampus and in all parts of the contralat eral side, TUNEL staining or caspase-3 immunoreactiv ity was not found in this experiment. Moreover, changes in cytochrome c immunoreactivity were not detected in any parts except for the ipsilateral ischemic area. No staining cells were detected in the sample treated without each primary antibody as negative control (data not shown). There was no leukocyte infiltration except that around the needle track in one vehicle treated-rat, and traumatic injury was observed only around the needle track (data not shown).
DISCUSSION
We demonstrated that Ad-GDNF used in this study had the ability to infect 293 cells and produce 20-kDa GDNF (Fig. 1, lane 3) Staining was performed at 24 hours after transient MCAO, and was categorized into the following 4 grades: no staining, or a small (2-10), moderate (l0-100), or large (l00-500) number of stained cells into (-), ( ±) , (+), and (2+), respectively, Sham control, n = 2; vehicle and Ad-GDNF treated groups, n = 3. neuron degeneration (Choi-Lundberg et aI., 1997; Ko jima et aI., 1997; Mamdel et aI., 1997; Fan et aI., 1998) and improves behavioral impairment in the rat model of Parkinson's disease (Bilang-Bleuel et aI., 1997; Lapchak et aI., 1997) . Neuroprotective activity of adenovirus mediated GDNF gene transfer against axotomy-induced motoneuron death was also reported (Baumgartner and Shine, 199'4) . However, it has not been reported if ad enovirus-mediated GDNF gene transfer could protect more severe types of neuronal death such as with isch emia or stroke. In this experiment, we first demonstrated that adenovirus-mediated exogenous GDNF gene was successfully transferred into the cortical neurons (Figs. 5b and 5d, arrowheads) and attenuated ischemic brain injury after the transient MCAO model (Fig. 3) .
Several reports have shown that adenovirus vector it self induces proteins such as inflammatory cytokines (Cartmell et aI., 1999) , adhesion molecules (Newman et aI., 1995) , or stress proteins (Kitagawa et aI., 1998b,c) . There is a possibility that injection of the vector itself could influence or protect ischemic brain injury after transient MCAO. However, Ad-LacZ injection (used as a control vector) did not affect the infarction that occurred after transient MCAO (Fig. 3) . Therefore, the neuropro tective effect of Ad-GDNF may be due to exogenous GDNF gene product.
GDNF gene expression was only detected in the cor tical neurons around the injection site ( Figs. 5b and 5d ), and GDNF contents around needle route were 300 pg/ 100 mg tissue (Fig. 4) . GDNF binds GDNF receptor a (GFRa-l) with a Kd value of 3 pmol/L and mediated the survival response of cultured neurons at 1 pg/mL to 10 ng/mL in in vitro study (Treanor et aI., 1996; Klein et aI., 1997) . Moreover, previous gene transfer studies against neurodegeneration showed that similar levels of the gene product produced evident neuroprotective effect (Mandel et aI., 1997) . Therefore, the GDNF content in the present J Cereh Blood Flow Metab. Vol. 19. No. 12. 1999 study is probably sufficient to possess a protective effect. In our previous study, GDNF immunoreactivity was en dogenously induced in neurons after transient MCAO (Abe and Hayashi, 1997) . However, neither GDNF mRNA nor protein immunoreactivity was detected in the normal rat brain, and the induction of GDNF protein was only temporally seen (1 to 3 h) in the early phase of transient MCAO (Abe and Hayashi, 1997) . Therefore, the immunoreactive GDNF detected before or 24 hours after 90 minutes of transient MCAO (Figs. 5b and 5d ) in the present study may predominantly be of adenovirus mediated origin.
The protective mechanism of GDNF has not been fully understood, although previous work has demon strated that GDNF diminished ischemia-induced nitric oxide release (Wang et aI., 1997) or reduced caspase immunoreactive neurons (Kitagawa et aI., 1998a) . In the present study, there was no significant difference in rCBF among the vehicle-, Ad-LacZ-, and Ad-GDNF treated groups (Fig. 2) , suggesting that the effect of Ad GDNF was not associated with the improvement of rCBF. GDNF signaling is mediated by the receptor ty rosine kinase encoded by the c-ret proto-oncogene (Ret) (Durbec et aI., 1996; Trupp et aI., 1996) , and GFRa-1, a glycosyl-phosphatidylinositol-linked protein, assists in GDNF binding to Ret (Treanor et aI., 1996; Klein et aI., 1997) . Distribution of Ret and GFRa-l mRNA expres sions in the rat central nervous system was recently re ported. GFRa-1 mRNA was detected in the cerebral cor tex, whereas Ret mRNA was not seen in the normal rat brain (Trupp et aI., 1997; Glazner et aI., 1998) . However, both GFRa-l and Ret mRNAs were markedly induced in the pyramidal layer of the cerebral cortex 12 to 24 hours after kainic acid treatment (Trupp et aI., 1997) . There fore, GDNF/Ret/GFRa-1 interactions may also occur in the ischemic condition. Further study seems to be re quired to confirm that the interaction of GDNF and its receptors could be essential for its neuroprotective effect in ischemic brain injury.
Our previous study suggested that protective effect of GDNF on ischemic brain injury was associated with the inhibition of immunoreactive caspases -1 and -3 (Kitagawa et aI., 1998a) . Of interest is that one of the most important pathways of neuronal death is related to mitochondrial dysfunction (Abe et aI., 1995) . Recently, it has been demonstrated that cytochrome c release from mitochondria to cytosol activates the caspase cascade in vitro (Kluck et aI., 1997; Yang J et aI., 1997) . Further more, cytosolic redistribution of cytochrome c after tran sient focal cerebral ischemia in rats was demonstrated (Fujimura et aI., 1998) , suggesting a vital role in neuro nal cell death. In the present study, both immunoreactive caspase-3 and cytochrome c were induced in the cyto plasm of neuronal cells in the penumbral cortex after transient ischemia ( Figs. 6e and 6h , arrowheads) and obviously decreased in the Ad-GDNF-treated group (Figs. 6f and 6i, arrowheads) with correspondence to TUNEL-staining profiles ( Figs. 6b and 6c ). Although the TUNEL method is not specific for apoptotic neurons in the ischemic brain, the TUNEL-positive neurons in the ischemic penumbral region are mainly apoptotic cells, whereas those in the ischemic core are necrotic (Charri aut- Marlangue et aI., 1996) . Therefore, some of the TUNEL-positive neurons observed in the present study died by apoptotic process. Thus, the apoptotic pathway via cytochrome c and caspase-3 seems to be one of the targets of protection by GDNF. In this study, we have demonstrated the change of immunoreactive caspase-3 protein after transient MCAO, but the pro-or activated form of caspase-3 has not been examined. Further study of the change of caspase-3 activity would provide us the precise information about the protective mechanism of GDNF.
Gene therapeutic study for stroke has not yet been tried in the clinical situation. Although it has been dem onstrated that adenovirus-mediated neuronal apoptosis inhibitory protein or an interleukin-I receptor antagonist had a protective effect against ischemic brain injury, ad enoviral vectors were injected 5 days before ischemia (Betz et aI., 1995; Xu et aI., 1997) . Herpes simplex virus mediated HSP72 gene transfer markedly improved stria tal neuron survival in focal ischemia, but the vector was injected 8 hours before occlusion (Yenari et aI., 1998) . In this study, adenoviral vector was also injected 24 hours before MCAO, because it takes more than 8 hours to express the gene product using the adenoviral vector in the normal rat brain (Abe et aI., 1997b) . However, gene therapy should be applied after an occurrence of stroke in the clinical situation. Therefore, therapeutic study with these vectors should be examined when delivered after ischemia. Furthermore, each vector has some disadvan tages such as toxicity or efficacy of gene expression. Improvement of vectors or development of a safer vector may be necessary for more practical gene therapy. Fi nally, the route of administration may be of major con cern for gene therapy. In the present study, we adminis trated the vector directly into the cerebral cortex. Of course, direct injection of the vector may not be practical in clinical application. Although intraarterial or venous administration could be more suitable for human isch emic diseases, there may be great difficulty in delivering the vector specifically to the ischemic area. When these problems are successfully resolved, gene therapy could have great potential for stroke therapy in the future.
